Platinib price introduction in 2024

Pralsetinib is an innovative anti-cancer drug that specifically targets cancers carrying RET gene mutations. It is the first selective RET inhibitor approved for marketing in China and is of great significance for the treatment of specific types of cancer. Platinib effectively inhibits the activity of RET receptor tyrosine kinase, thereby inhibiting the growth of cancer cells carrying RET fusion genes, providing a new and powerful weapon in the fight against cancer.

Platinib’s scope of application is mainly focused on the treatment of locally advanced or metastatic non-small cell lung cancer, especially those patients with RET fusion gene positivity. In addition, platinib has also shown significant efficacy in the treatment of advanced or metastatic RET-mutant medullary thyroid cancer, as well as advanced or metastatic RET fusion-positive thyroid cancer that is refractory to radioactive iodine therapy.

The emergence of platinib has brought new treatment hope to patients with these specific types of cancer. Its unique mechanism of action enables it to accurately attack cancer cells while reducing damage to normal cells. In clinical trials, platinib has proven its safety and efficacy, bringing substantial disease relief and improvement in quality of life to many patients.

It is worth mentioning that the development and application of platinib reflects modern medicine’s pursuit of precise treatment. By targeting specific gene mutations, targeted therapy not only improves the therapeutic effect, but also reduces unnecessary side effects. This personalized treatment strategy is gradually becoming an important direction in future cancer treatment.

Platinib is currently on the market in China, and patients can purchase it directly from China. The domestically marketed Platinib is produced by Catalent CTS in the United States, with a specification of 100mg*120 tablets and a price of about 20,000 yuan per box. Unfortunately, Platinib has not yet been included in my country's medical insurance reimbursement items. It is understood that the original drug specification of Platinib marketed overseas is 100mg*60 tablets, the US version is priced at 159,000 yuan per box, and the European version is priced at around 45,000 yuan. In addition, there is already a generic version of Platinib on the market in Lucius, Laos, with a specification of 100mg*120 tablets and a price of about 4,600 yuan. If the patient has more questions about platinib, please consult a regular overseas medical consulting company.

In general, Platinib is a treatment forInnovative anti-cancer drugs based on RET gene mutations provide new treatment options for patients with various cancers. Its unique mechanism and significant therapeutic effect make it occupy an important position in the field of anti-cancer, bringing more hope and possibilities to cancer patients.